225 related articles for article (PubMed ID: 33705837)
1. Potential of Pueraria tuberosa (Willd.) DC. to rescue cognitive decline associated with BACE1 protein of Alzheimer's disease on Drosophila model: An integrated molecular modeling and in vivo approach.
Ahuja A; Tyagi PK; Tyagi S; Kumar A; Kumar M; Sharifi-Rad J
Int J Biol Macromol; 2021 May; 179():586-600. PubMed ID: 33705837
[TBL] [Abstract][Full Text] [Related]
2. BACE1 Inhibition by Genistein: Biological Evaluation, Kinetic Analysis, and Molecular Docking Simulation.
Youn K; Park JH; Lee S; Lee S; Lee J; Yun EY; Jeong WS; Jun M
J Med Food; 2018 Apr; 21(4):416-420. PubMed ID: 29444415
[TBL] [Abstract][Full Text] [Related]
3. Identification of new BACE1 inhibitors for treating Alzheimer's disease.
Kushwaha P; Singh V; Somvanshi P; Bhardwaj T; Barreto GE; Ashraf GM; Mishra BN; Chundawat RS; Haque S
J Mol Model; 2021 Jan; 27(2):58. PubMed ID: 33517514
[TBL] [Abstract][Full Text] [Related]
4. Computational modelling of potent β-secretase (BACE1) inhibitors towards Alzheimer's disease treatment.
Ugbaja SC; Sanusi ZK; Appiah-Kubi P; Lawal MM; Kumalo HM
Biophys Chem; 2021 Mar; 270():106536. PubMed ID: 33387910
[TBL] [Abstract][Full Text] [Related]
5. Comparative Evaluation of the Antioxidant and Anti-Alzheimer's Disease Potential of Coumestrol and Puerarol Isolated from Pueraria lobata Using Molecular Modeling Studies.
Koirala P; Seong SH; Jung HA; Choi JS
Molecules; 2018 Mar; 23(4):. PubMed ID: 29597336
[TBL] [Abstract][Full Text] [Related]
6. Identification of new BACE1 inhibitors using Pharmacophore and Molecular dynamics simulations approach.
Dhanabalan AK; Kesherwani M; Velmurugan D; Gunasekaran K
J Mol Graph Model; 2017 Sep; 76():56-69. PubMed ID: 28710924
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
Luo X; Yan R
Int J Clin Exp Pathol; 2010 Jul; 3(6):618-28. PubMed ID: 20661410
[TBL] [Abstract][Full Text] [Related]
8. Biological Evaluation and Docking Analysis of Potent BACE1 Inhibitors from
Youn K; Jun M
Nutrients; 2019 Mar; 11(3):. PubMed ID: 30893825
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
10. BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism.
Stern AL; Ghura S; Gannon PJ; Akay-Espinoza C; Phan JM; Yee AC; Vassar R; Gelman BB; Kolson DL; Jordan-Sciutto KL
J Neurosci; 2018 May; 38(18):4288-4300. PubMed ID: 29632166
[TBL] [Abstract][Full Text] [Related]
11. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
Read J; Suphioglu C
Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of quinazolinone-based hydrazones with potential use in Alzheimer's disease.
Haghighijoo Z; Firuzi O; Hemmateenejad B; Emami S; Edraki N; Miri R
Bioorg Chem; 2017 Oct; 74():126-133. PubMed ID: 28780149
[TBL] [Abstract][Full Text] [Related]
13. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
[TBL] [Abstract][Full Text] [Related]
14. Targeting the β secretase BACE1 for Alzheimer's disease therapy.
Yan R; Vassar R
Lancet Neurol; 2014 Mar; 13(3):319-29. PubMed ID: 24556009
[TBL] [Abstract][Full Text] [Related]
15. Identification of potential lead compounds against BACE1 through in-silico screening of phytochemicals of Medhya rasayana plants for Alzheimer's disease management.
Nadh AG; Revikumar A; Sudhakaran PR; Nair AS
Comput Biol Med; 2022 Jun; 145():105422. PubMed ID: 35354103
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
17. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
Barão S; Moechars D; Lichtenthaler SF; De Strooper B
Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
[TBL] [Abstract][Full Text] [Related]
18. Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer's Disease.
Naushad M; Durairajan SSK; Bera AK; Senapati S; Li M
Planta Med; 2019 Nov; 85(17):1316-1325. PubMed ID: 31618777
[TBL] [Abstract][Full Text] [Related]
19. Identification of Novel BACE1 Inhibitors by Combination of Pharmacophore Modeling, Structure-Based Design and In Vitro Assay.
Ju Y; Li Z; Deng Y; Tong A; Zhou L; Luo Y
Curr Comput Aided Drug Des; 2016; 12(1):73-82. PubMed ID: 26899408
[TBL] [Abstract][Full Text] [Related]
20. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Moussa CE
Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
